Company
Affinia Therapeutics
| Industry | gene therapy company with a pipeline of first-in-class and/or adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases |
|---|
Funding raised
| Company | Round | Date |
|---|---|---|
| Affinia Therapeutics | Series C | 2025-10-08 |